Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 13/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | TOP2A | P11388 | 2/20 | 0.61 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.61 |
| ▸ | HTR1D | P28221 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5476725 | 0.89 | NISCH (0.79) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL2513540 | 0.88 | NISCH (0.68) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL3262379 | 0.82 | NISCH (0.69) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL17826831 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL1685409 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL1882160 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL8141372 | 0.79 | NISCH (1.00) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL771337 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL1209074 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL1886692 | 0.79 | NISCH (1.00) | NISCHLMNARECQLTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | claimed |
| CN-101528681-B | New sulfonamide derivatives as bradykinin antagonists | RITCHER GEDEON NYRT | 2013-01-30 | — | — | CN | claimed |
| CN-101341125-B | New phenanthridine derivatives as bradykinin antagonists | RICHTER GEDEON NYRT | 2012-10-10 | — | — | CN | claimed |
| US-8034827-B2 | Phenanthridine derivatives as bradykinin antagonists | Richter Gegeon Nyrt. (HU) | 2011-10-11 | — | — | US | claimed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | claimed |
| US-20090270411-A1 | PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | claimed |
| CN-101528681-A | New sulfonamide derivatives as bradykinin antagonists | RITCHER GEDEON NYRT (HU) | 2009-09-09 | — | — | CN | claimed |
| EP-2074083-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-07-01 | — | — | EP | claimed |
| CN-101341125-A | New phenanthridine derivatives as bradykinin antagonists | RICHTER GEDEON NYRT (HU) | 2009-01-07 | — | — | CN | claimed |
| EP-1966142-A2 | NEW PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2008-09-10 | — | — | EP | claimed |
| WO-2008050168-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | claimed |
| WO-2007072092-A2 | NEW PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | claimed |
| CN-1849121-A | Piperazine derivatives as bradyknin antagonist | AMGEN INC (US) | 2006-10-18 | — | — | CN | claimed |
| EP-1656355-A2 | PIPERAZINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-05-17 | — | — | EP | claimed |
| WO-2005061467-A2 | PIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS | AMGEN INC. (US) | 2005-07-07 | — | — | WO | claimed |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | AMGEN INC. | 2005-01-20 | — | — | US | claimed |
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| CN-101528681-B | New sulfonamide derivatives as bradykinin antagonists | RITCHER GEDEON NYRT | 2013-01-30 | — | — | CN | disclosed |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | AMGEN INC. | 2005-01-20 | — | — | US | disclosed |
| US-5686456-A | DIARYLPYRIMIDINES | THE UNIVERSITY OF NORTH CAROLINA (US) | 1997-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270411-A1 | PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB2, BDKRB1, HRH2 | NISCH 131/4885LMNA 2729/4885RECQL 2167/4885 |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | NISCH 95/4885LMNA 2003/4885RECQL 1573/4885 |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | ACHE, TNF, BCHE | NISCH 472/4885LMNA 3433/4885RECQL 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.